|
Session 118
Poster Abstracts
Acute HIV Infection: Treatment
Monday, 1-4 pm
Room: Hall A |
693
 |
Interrupted ART of Acute Compared with Recent HIV Infection: Final Results of ACTG 371
Paul Volberding*1, E Connick2, R Bosch3, E Aga3, C Pettinelli4, M Hirsch3, M Vogler5, S Little6, L Demeter7, and AIDS Clinical Trials Group
1Univ of California, San Francisco, US; 2Univ of Colorado, Denver, US; 3Harvard Univ, Boston, MA, US; 4NIAID, NIH, Bethesda, MD, US; 5New York Univ, New York, US; 6Univ of California, San Diego, US; and 7Univ of Rochester, NY, US |
694
|
Early Short-course HAART Initiated at the Time of Primary HIV Infection Provides No Sustained Benefit in Terms of Time to CD4 Decline below 350/mm3: Results of a Propensity Analysis within the ANRS PRIMO Cohort
L Desquilbet1, Bruno Hoen*2, C Goujard3, C Deveau1, J Warszawski1, L Meyer1, and the ANRS PRIMO Cohort study group
1INSERM U822, Le Kremlin Bicetre, France; 2Univ Hosp Besancon, France; and 3Hosp Bicetre, Le Kremlin Bicetre, France |
695
|
Can HAART Initiation at Early Acute HIV Infection Benefit the Immune-virology Outcome Despite Subsequent Treatment Cessation? The ANRS Reservoirs’ Study Group
Thierry Prazuck*1, A Lafeuillade2, L Hocqueloux1, J P Viard3, V Avettand Fenoel4, and C Rouzioux4
1Ctr Hosp Regional Orleans La Source, France; 2Hosp Chalucet, Toulon, France; 3Ctr Hosp Univ Necker, Paris, France; and 4Ctr Hosp Univ Necker, Paris, France |
696
|
Early Initiation of HAART during Primary HIV Infection Enhances CD127 Expression and Proliferative Capacities of HIV-specific CD8+ T Cells
Camille Lecuroux*1, I Girault1, O Lambotte1, A Urrutia1, F Boutboul2, B Autran2, M Sinet1, A Venet1, and the ANRS CO6-PRIMO Cohort and the ANRS EP36-HIC Study Group
1INSERM U802, Paris XI, Hosp Bicetre, Le Kremlin Bicetre, France and 2INSERM U543, Hosp Pitie-Salpetriere, Paris, France |
697
|
The Effect of ART of Different Durations in Primary HIV Infection
N Pantazis1, Giota Touloumi*1, P Vanhems2, J Gill3, K Porter4, and CASCADE Collaboration
1Athens Univ Med Sch, Greece; 2CNRS UMR 5558, Univ Lyon 1, France; 3Southern Alberta HIV Clin, Calgary, Canada; and 4Med Res Council Clinical Trials Unit, London, UK |
698a
|
A Multi-state Markov Model for the Natural History of Recent, Drug-naive HIV-1 Infection and the Initiation of ART
Lorne Walker*, S Frost Ph.D., and S Little M.D.
Univ of California, San Diego, US |
698b
|
Temporary ART during Primary HIV-1 Infection Lowers the Viral Set-point: The Prospective, Randomized Primo-SHM Study
Radjin Steingrover*1,2,3, I Schellens4, A Verbon5, K Brinkman6, A Zwinderman4, S Jurriaans2, F Miedema4, J Lange4, D van Baarle4, and J Prins1,2
1Ctr for Infection and Immunity Amsterdam, The Netherlands; 2Academic Med Ctr, Amsterdam, The Netherlands; 3Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; 4Univ Med Ctr, Utrecht, The Netherlands; 5Academic Hosp Maastricht, The Netherlands; and 6Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands |
698c
|
An Open-label Randomized Trial to Determine the Virologic and Immunologic Effects of 4-Weeks of Cyclosporine A Given in Combination with ART during Acute and Early Infection
Martin Markowitz*1, F Vaida2, S Little2, B Hare3, H Balfour4, E Ferguson5, K Schafer2, D Richman2, and the AIN 501 and ACTG 5216 Study Team
1Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; 2Univ of California, San Diego, US; 3Univ of California, San Francisco, US; 4Univ of Minnesota, Minneapolis, US; and 5Div of AIDS, NIH, Bethesda, MD, US |
|
